Common polymorphisms within the human UGT1A gene locus are associated with irinotecan and tranilast toxicity. To uncover additional functional variation across this gene cluster, cross-species sequence comparisons were performed. Evolutionarily conserved segments (a total of 47.1 kb) were re-sequenced in 24 African-American, 24 European-American, and 24 Asian individuals, and 381 segregating sites (including 123 singletons) were identified. Highly conserved coding sites were less likely to be polymorphic than diverged sites (Po0.0001) but this pattern was not observed at noncoding sites (P ¼ 0.1025). Among coding variants, the distribution of those computationally predicted to affect function was skewed toward low frequencies. Some alleles occurred at similar frequencies in each population; others had wide disparities. Although strong linkage disequilibrium was detected among the hepatically expressed genes, the degree of linkage disequilibrium varied among populations. These results suggest that rare functional gene variants and inter-population variability must be considered in the interpretation of association studies between UGT1A and drug metabolism/toxicity phenotypes.
Introduction
Vertebrates evolved with the UGT (UDP-glucuronosyltransferase) gene family, 1,2 a set of endoplasmic reticulum-specific enzymes that catalyze the transfer of glucuronic acid from uridinediphospho-glucuronic acid to various lipophilic substrates. This reaction is crucial to the processing of bilirubin and endogenous hormones, the elimination of therapeutic drugs from the circulation, and the inactivation of environmental toxins. The human UGT1A locus on chromosome 2q37 contains 13 promoters/first exons that encode nine proteins sharing a common C-terminus encoded by the 3 0 exons 2-5. 3 The lead exon in any given transcript is predicted to be spliced to the four common exons to generate a functional enzyme. Each product is named for the UGT1A locus and an additional number representing the spliced first exon. For the enzyme product, this lead exon encodes the amino-terminal substrate specificity and the common exons encode the UDP-glucuronic acid-accepting domain. This multiple tandem exon structure is a shared feature of several important genes and may provide a common mechanism for directing cell-and tissue-specific gene expression.
Products of the UGT1A locus metabolize endogenous molecules such as thyroxine, estrone, and bilirubin. Of the nine UGT1A isoenzymes, UGT1A1 has the greatest bilirubinconjugating activity, 1 required for elimination of bilirubin. Diminished production or activity of this enzyme leads to the hyperbilirubinemic syndromes described by CriglerNajjar and Gilbert [5] [6] [7] [8] ; these syndromes have been associated with several common and rare variants of UGT1A1.
1, [8] [9] [10] [11] Genome-wide scanning of healthy human pedigrees has linked serum bilirubin levels most strongly to the chromosome 2q37 region containing UGT1A. 12 However, bilirubin levels also depend on the rate of production of bilirubin. Hence, the severity of inherited hemolytic syndromes such as glucose 6-phosphate dehydrogenase deficiency and sickle cell anemia may be exacerbated or mitigated by variants of UGT1A and these interactions may have affected the evolutionary history of this gene in different human populations. [13] [14] [15] While the primary selective pressure for UGT1A enzyme function may have been metabolism of endogenous molecules, UGT1A function is necessary for elimination of exogenous compounds such as the anti-cancer drug irinotecan. [16] [17] [18] The same common UGT1A1 variants associated with mild elevations of serum bilirubin are associated with diminished in vitro glucuronidation of the active irinotecan metabolite, SN-38, [19] [20] [21] [22] and prolonged exposure and increased toxicity in patients receiving this agent. [23] [24] [25] As shown by Sai et al., 25 re-sequencing of the UGT1A1 gene in 85 Japanese patients treated with irinotecan confirmed that the haplotypes containing lower expression variants were associated with both a low SN-38G/SN-38 AUC ratio and elevated pretreatment bilirubin concentration. Importantly, however, additional haplotypes appeared to have distinct modifying effects on the SN-38 AUC ratio and total bilirubin level phenotypes, suggesting that more complete genetic variation data for UGT1A may better predict bilirubin and irinotecan metabolism phenotypes. As common genetic variants of the UGT1A locus may better predict toxicity of irinotecan than conventionally used variables, 26 ongoing clinical trials have been designed to test the safety and efficacy of adjusting doses of irinotecan according to patients' UGT1A genotypes.
For the anti-keloid/anti-allergy agent tranilast, hyperbilirubinemia is a common toxicity. 27 A staged, genome-wide analysis has associated three single nucleotide polymorphisms (SNPs) of the UGT1A locus with this toxicity. 28 Although it is reasonable to assume that the association between hyperbilirubinemia and these pharmacologic agents is based on genetic variation at UGT1A1, for other metabolic/ toxicologic phenotypes of UGT1A, the overlapping tissue distributions and substrate affinities of enzymes encoded by this locus may complicate interpretation of single genotype or single exon-haplotype association studies. As suggested by the results of Sai et al., 25 detailed knowledge of the interindividual genetic variability across this region, especially if focused on the segments most likely to affect expression and activity of these enzymes, could yield a better understanding of the pathopharmacology of new drugs.
The analysis of patterns of human variation is an important prerequisite for designing association studies aimed at assessing the role of genetic variation in drug response phenotypes. Re-sequencing approaches to the study of human variation may provide information to clarify the relative roles of common and rare variants on gene regulation and function. For UGT1A, a re-sequencing approach is complicated by the size of the region, spanning approximately 200 kb. Many previous studies of the breadth of human diversity of pharmacologically relevant genes have focused on exon re-sequencing and in vitro assays of protein function. 29, 30 Such studies are likely to identify many functional variants, but may miss functional noncoding sequence variants, 31 as have already proved important for UGT1A1. 8, 11, 32 To focus on the regions of the entire UGT1A locus most likely to affect clinical phenotypes, we identified 29 kb of non-coding sequence highly conserved between humans and four mammalian species and resequenced these regions as well as over 8 kb of exon sequence in 72 individuals from three ethnic populations.
Typically, genotype/phenotype association studies of UGT1A have been performed on populations derived predominantly from a single population (e.g. Japanese, European, European-American), but the variants selected for genotyping are often based on allele frequency data generated from a population of greater ethnic diversity than the test group. To provide information useful to the interpretation of published studies and the design of future studies we present (1) a comparative genomics analysis aimed at identifying evolutionary conserved regions most likely to affect UGT1A function, (2) the relationship between the degree of sequence conservation across species and the proportion of polymorphic variants at conserved coding and non-coding sites, (3) the frequency distribution of coding variants as a function of the probability of an effect on enzyme function, and (4) differences in allele frequency and linkage disequilibrium (LD) of newly and previously identified variants in European-Americans, Asians, and AfricanAmericans.
Results

Multispecies comparative genomics of UGT1A
We compared the genomic sequence of the UGT1A gene cluster in human, baboon, dog, rat, and mouse. These five mammalian species span a total common ancestry of greater than 300 million years (Mya) 33, 34 and sample three deep branches of the mammalian phylogeny (primates, rodents, and carnivores) that diverged from each other more than 80 Mya. Thus, elements showing a high degree of sequence similarity across this set of species are likely to be due to active conservation resulting from functional constraints rather than limited divergence time. Figure 1 shows the percent sequence identity between the human reference sequence and the sequence of each of the four species. As a result of different duplication and deletion events, the genomic organization of the UGT1A gene cluster varies across mammalian species.
2 Hence, our approach was to generate all local alignments between the human reference sequence and the most similar sequence stretch in each of the other species regardless of whether paralogous or orthologous segments were aligned (see Materials and methods). Because our goal is to identify elements that are likely to be functional in humans, this approach is conservative. Based on the notion that conserved sequences may contain functional elements, these data were used to select relevant regions to be re-sequenced in human population samples. High sequence similarity is observed for the coding regions of active genes. In addition, 1-5 kb of non-coding sequences adjoining the first exons as well as two non-coding regions 5 0 and 3 0 to the shared exons show substantial sequence similarity across all species. These conserved coding and non-coding regions, labeled with green bars across the top of the plot in Figure 1 , were included in our re-sequencing survey. Several regions of high sequence similarity, but unlikely to affect UGT1A function, were excluded from the re-sequencing survey. These include the first exons and adjoining non-coding sequences for the UGT1A pseudogenes (UGT1A2p, 11p, 12p, and 13p), and two regions of high sequence similarity between exons UGT1A3 and 1A2p and between UGT1A2p and 1A1. These regions are identical to mRNA transcripts with homology to the chaperone protein DNAj (AY083665 and BC066346, respectively).
The nucleotide positions of the start and stop sites for each surveyed segment are detailed in Table 1 . As the selected regions include coding as well as non-coding sequence 5 0 and 3 0 of the first exons, the regions are denoted by Roman numerals corresponding to the Arabic numerals for the contiguous UGT1A exon (e.g. VIII for UGT1A8). Of note, segment I extends upstream to include the phenobarbital response enhancer module 5 0 of UGT1A1. 35 The region labeled 3 0 represents the sum of four segments in the 3 0 end portion of the gene cluster, which contains the shared exons coding for the enzyme C-terminus. The segments coincide with conserved non-coding sequence 5 0 to the exons, exons 2-4, exon 5, and a region of 3 0 conserved non-coding sequence.
Patterns of human polymorphism across sites with varying degrees of cross-species conservation As functional constraints are expected to shape both inter-species sequence divergence and within-species Given a five species sequence alignment, for each nucleotide position in the human reference sequence, there are 16 possible patterns of conservation ( Table 2 ). The least frequent patterns were those in which nucleotide positions were concordant across two or three of the deep branches of the mammalian phylogeny but were discordant across both pairs of closely related species (i.e. human-baboon and ratmouse). The most frequent pattern was the one in which all five species were concordant, probably reflecting our choice of segments with higher sequence similarity; the proportion of completely concordant positions was greater in the coding (61.4%) compared to the non-coding (22.8%) regions. Finally, the rat-mouse comparison displayed a larger proportion of discordant sites (18%) than the human-baboon comparison (9%).
To assess the evolutionary significance of mutations generating polymorphic alleles in humans, it is useful to infer the ancestral allele at each polymorphic site. The baboon sequence was used to infer the ancestral allele at each human polymorphic site, which was then used as the reference allele in the cross-species comparison. Each site (invariant or polymorphic) in the human sequence was then examined for its level of conservation across the remaining three species and assigned to one of two major classes: highly conserved, if the human reference nucleotide is identical in dog, rat, and mouse, and divergent, if the human reference nucleotide is different in one or more of the other three species.
For the 47.1 kb sequenced for each of 72 individuals, 381 variable sites were identified (of which 123 were singletons). Once each site in the human reference sequence was classified according to the degree of cross-species conservation, we calculated the summary statistics of polymorphism for each of the two classes of conservation (shown in Table  3 ). The amount of polymorphism was summarized by two commonly used statistics: nucleotide diversity (p), 36 based on the average heterozygosity, and y W , based on the number of polymorphic sites and sample size. 37 As expected, the amount of polymorphism is lower in the highly conserved compared to the diverged class of sites. However, this difference is more pronounced in the coding compared to the non-coding regions. The probability of a highly conserved coding site to be polymorphic in humans is These results suggest that, even though the highly conserved sites in both coding and non-coding regions have the same configuration across the five mammalian species compared, functional constraints operate differently in the coding compared to the non-coding regions. This contention receives some support from the analysis of the frequency spectrum at highly conserved and diverged sites in coding and noncoding regions. More specifically, the highly conserved coding sites have a stronger skew toward rare variants (as reflected by the smaller value of Tajima's D) 36 than the diverged coding sites, but no difference is observed for noncoding sites (Table 3) . Altogether, these results suggest that functional variants in coding sequences tend to be more tightly constrained than those in non-coding sequences.
Prediction of functional effects of amino-acid replacement variants
Extrapolating from data on Mendelian diseases, it has been proposed that the greatest proportion of functional effects are attributable to non-synonymous sequence variants. 31, 38 In addition, genome-wide analyses of coding polymorphisms revealed that amino-acid replacement variants tend to occur at lower frequencies compared to silent variants, consistent with the idea that non-synonymous polymorphisms tend to have deleterious effects. [39] [40] [41] Furthermore, investigations of specific genotype/phenotype relationships have demonstrated that rare amino-acid replacement variants with strong functional effects may significantly affect common phenotypes. 42, 43 In some cases, synonymous polymorphisms also have been shown to have equally striking effects on phenotype. 44 These data taken together indicate that identification of common as well as rare functional variants will be necessary to predict accurately a latent phenotype such as slow metabolism of a specific pharmacologic agent.
Across the 8484 bp of coding sequence (out of the total 47.1 kb total sequence per individual) surveyed in 144 chromosomes, 93 coding SNPs (cSNP) were identified; of these, 32 were synonymous (sSNP) and 61 non-synonymous (nsSNP). We observe great variation with regard to the number of nsSNPs across the UGT1A first exons despite their similar length, with no variants observed in 1A9 and as many as 12 and 15 nsSNPs in 1A3 and 1A10, respectively. In UGT1A10 most nsSNPs occur as singletons and all are rare, whereas in UGT1A3 two of the nsSNPs occur at intermediate frequency (i.e. 410%). Several cSNPs within the first exon of UGT1A3 have been tested in vitro for estrone glucuronidation activity. 45 Interestingly, the variant demonstrating 300% increased activity relative to 'wild type' has been reported as 140 T-C (V47A), as the C variant represents the minor allele in the Japanese population where the functional studies were performed. However, C is likely the ancestral allele as it is present in baboon. Also, C is the major allele among African-Americans with a frequency of 71%, whereas it is the minor allele at a frequency of 30% among European-Americans, and more rare among Asians at 9%.
To predict functional significance of coding variants, Ng and Henikoff [46] [47] [48] developed an algorithm based on evolutionary conservation, SIFT (sorting intolerant from tolerant). This algorithm uses a query sequence to search for similar sequences that may share similar function, generates the alignment of the chosen sequences, and calculates the Site configurations in a five-species sequence alignment and proportion of sites in the human reference sequence for each configuration. The 0's and 1's indicate, respectively, a site that is different from or identical to the human reference sequence.
probabilities for all possible substitutions in the alignment.
In one large database, 69% of coding changes known to be associated with abnormal physiology were predicted by SIFT to have functional consequences. 48 To increase the sensitivity of the algorithm, some have altered the threshold score for declaring functional significance from 0.05 to 0.1. 30, 46, 49 This choice is supported by the UGT1A1*6 (G71R) variant, which has been shown to influence serum bilirubin levels in several independent studies 9,10,50-57 although it has a SIFT score of 0.1.
If the SIFT algorithm identifies functional variants and these variants have deleterious effects on the phenotype, the predicted functional variants should occur at lower frequencies compared to non-functional, neutrally evolving variants. To test this hypothesis, we compared the spectrum of allele frequencies for all the cSNPs identified in this survey categorized by their predicted functional significance. As shown in Figure 2 , nsSNPs at the most highly conserved coding sites (defined as having SIFT scores p0.1) have a skewed distribution toward lower frequency alleles compared to nsSNPs with higher SIFT scores (KolmogorovSmirnov test P ¼ 0.0231) and to sSNPs (P ¼ 0.0314). Five nsSNPs had a SIFT score between 0.05 and 0.10. Three of these five nsSNPs occurred as singletons in the entire data set, whereas the remaining two occurred at intermediate frequency in one or two population samples; one of the two intermediate frequency variants is the aforementioned and well-characterized UGT1A1*6 (G71R) SNP. Furthermore, when the minor allele frequency of each nsSNP is compared to the corresponding SIFT score, a statistically significant rank correlation is observed (Spearman rank correlation P ¼ 0.0485). This implies that the SIFT algorithm may provide information over the entire range of predicted functional effects.
As expected based on evolutionary considerations and as previously proposed for pharmacologically relevant genes, 30 these results taken together suggest that a large fraction of coding variation in UGT1A is constrained. Although most functional variants occur at low frequencies, a minority of functional variants, such as UGT1A1*6 (G71R), occur at intermediate frequencies in individual populations. This raises the possibility that these variants were driven to higher frequencies owing to local selective pressures.
Comparison of UGT1A allele frequencies among populations As some variants, such as UGT1A1*6, are relatively common, but essentially limited to a single population, knowing the frequency and distribution of such variants might inform the interpretation of genotype-phenotype association studies. To this end, we selected the 180 common variants (arbitrarily defined as having minor allele frequency 47% in at least one population) in our data set and plotted their minor allele frequency as a function of their location in the reference sequence (Figure 3 ). For variants with different minor alleles in different populations, the less common variant in the global sample was determined to be the minor allele.
The patterns of allele frequencies varied over the different regions. In some first exon regions such as V and IV, variant allele frequency is low and nearly uniform. For regions X, IX, VII, and VI, allele frequencies tend to be higher, but relatively similar across the populations. However, there are wider disparities in allele frequency among the populations for regions III and I. Of 180 common variants, 15 are 'private' alleles -10 detected only in African-Americans and five only in Asians. Additionally, 33 of the 180 variants have an allele frequency difference greater than 30%; most of these differences occur between African-Americans and Asians.
Patterns of variation and LD in the major UGT1A liver isoforms The UGT1A1, UGT1A6, and UGT1A9 isoforms are primarily hepatically expressed and have been demonstrated to share affinity for certain substrates.
1, 58 Given their redundancy in the liver and overlapping catalytic function, the combination of variants for these three enzymes may have greater impact on the phenotype of specific substrate metabolism than any individual polymorphic site. Determining the haplotype structure spanning these genes in different ethnic groups may allow the design of more powerful association studies of bilirubin metabolism, drug pharmacokinetics, and cancer susceptibility. In African-Americans, segments IX, VI, I and the 3 0 region contain 101 variants, 35 of which are unique to this population. Over the same segments, the Asian and European-American populations each contained 81 variants, with 18 unique to the Asian population and 17 unique to the European-Americans. Among common variants (arbitrarily defined here as having minor allele frequency greater than 7% in the entire sample of 72 humans), 13 were found solely in African-Americans, four only in European-Americans, and two solely in Asians (including the functional variant UGT1A1*6 (G71R)).
In agreement with previously published surveys of LD, 59 -61 the overall rate of LD decay in African-Americans is greater than among Asians and European-Americans (Figure 4) . However, LD decay is not homogeneous across Figure 2 The distribution of cSNPs in the UGT1A locus. The histogram depicts the fraction of SNPs within each category on the Y axis by frequency cluster on the X axis. White bars represent the frequency distribution of sSNPs (coding amino acid unchanged), gray bars the non-synonymous amino-acid-changing SNPs predicted to not affect protein function by the SIFT algorithm, and black bars nsSNPs predicted by SIFT to affect protein function. Figure 3 Geographic distribution of common allele frequencies for each population. Location within the UGT1A reference sequence is plotted on the X axis (in kilobases), with each selected region marked by a separate box labeled in the upper right-hand corner. Allele frequency is marked on the Y axis. The frequency for each common variant is marked by blue triangles for the Asian population, red circles for the European-American population, and green squares for the African-American population. Black bars represent the exons within the region. Arrows highlight variants previously shown to be associated with human-health phenotypes in either multiple human subject studies or in individual association studies involving more than 100 human subjects; these include the UGT1A8*2 allele, 70,71 the three non-synonymous coding SNPs in UGT1A7 (*2,*3,*10), 69, 72, 73, 81, 82 two nsSNPs in UGT1A6 (*2,*3), 67, 68, 70 rs887829 -the SNP revealing the strongest association with tranilast-induced hyperbilirubinemia, 28 and the UGT1A1*6 allele. UGT1A comparative genomics ML Maitland et al these genes. A major area of LD decay is observed between segments VI and I, and is more pronounced in the nonAfrican compared to the African-American samples. In fact, LD between segments IX and VI is almost complete; implying that dissecting the independent contributions of UGT1A9 and UGT1A6 variants to drug response phenotypes in European-Americans and Asians will be particularly challenging and potentially irrelevant. In African-Americans, strong LD is limited to variants within segments IX and VI. In African-Americans and European-Americans, there is substantial LD decay in the 3 0 segment spanning the shared exons.
Discussion
In July 2005, the United States Food and Drug Administration approved a change to the irinotecan product label to consider genotyping patients for UGT1A1*28 before administering this drug. 62 For the agent tranilast, a phase III clinical trial failed to demonstrate significant reduction of restenosis after coronary artery stenting, 63 but with an appropriately powered, retrospective, genome-wide analysis, UGT1A1*28 was identified as a predictor of a common toxicity of tranilast -hyperbilirubinemia. 27, 28, 64 As early studies suggested this specific dinucleotide repeat to be important to clinical phenotypes, its variability among primates and human populations has been extensively characterized. 65, 66 However, other sites within the UGT1A locus may modify UGT1A1*28-associated phenotypes. Moreover, a variety of additional phenotypes have been associated with alleles within the UGT1A locus. [67] [68] [69] [70] [71] [72] [73] More data on human UGT1A genetic variants are expected to improve the robustness of their associations with the efficacy and adverse events of drugs. Although some data are already available, 74 current technology and cost limit comprehensive re-sequencing for candidate genes of every subject in every study. To focus on the variants most likely to control UGT1A activity and expression, we compared the genomic sequence of the UGT1A gene cluster across five mammalian species and identified a set of segments with a high degree of sequence similarity as candidate functional elements. Performed in ethnically diverse populations, our re-sequencing survey identified a large fraction of new coding and non-coding variants, and differences in allele frequency and LD among these variants in these three populations.
Coding and non-coding variants of UGT1A have been associated with important phenotypes, and the data in this re-sequencing study suggest that coding polymorphisms at highly conserved sites of UGT1A are more skewed toward low frequency than those occurring at diverged sites. No such trend is observed in non-coding sequences. A similar pattern was observed in genome-wide analysis of large sets of candidate genes for hypertension and other common diseases, 39, 41 and in membrane transporter genes likely to play a role in drug absorption, distribution, and elimination. 30 Our results for UGT1A non-synonymous polymorphisms are consistent with this large body of data and may imply that non-coding, potentially regulatory, variants occur at higher frequencies than coding variants affecting UGT1A activity. This scenario was proposed for the genetic variation in chromogranin A; functional variants were shown to include both common non-coding alleles that alter gene expression and rare amino-acid variants that alter the signaling function of this protein, which regulates catecholamine storage and release. 43 These results suggest that a combination of common and rare variants within the same gene may affect common phenotypes, including drug response.
Several non-synonymous variants with an effect on UGT1A function occur at intermediate frequencies in at least a subset of populations. These include the UGT1A1*6 (G71R) and the UGT1A3 (V47A) variants, both at higher frequency in Asians. These variants, although affecting function, might not have had fitness consequences and, thus, evolved neutrally. Alternatively, these variants may have been advantageous in some environments and, thus, were driven to intermediate frequency by positive natural selection. This scenario may be particularly relevant for the UGT1A1*6 variant, which was shown to be associated with reduced bilirubin glucuronidation and higher serum bilirubin levels, a trait previously proposed to have evolved under balancing selection. 15 In the case of the UGT1A3 V47A variant, we inferred that the derived allele is the one that occurs at high frequency in Asians; given the reduced activity associated with this allele, these results imply that either UGT1A3 is a dispensable gene or that the reduced UGT1A3 activity is advantageous in east Asian populations. It was previously proposed that variants in drug-metabolizing enzymes (DMEs) were likely targets of natural selection during the evolution of human populations and underlie human adaptations to different environments and diets. 75 Thus, the geographic distribution of the UGT1A1 and UGT1A3 variants discussed above may be explained within the broader context of DME evolution. Furthermore, our results suggest that even though functional non-synonymous variants at DME genes often occur at low frequencies, they may also reach intermediate frequencies depending on the selective pressures acting on them. Namely, whereas purifying selection probably kept deleterious variants at low frequency, positive selection may have shaped the frequency of advantageous variants in some populations.
The discrepancy in allele frequencies among different populations at different UGT1A loci suggests that typing population-specific variants may be necessary to predict more accurately drug toxicity in a patient from that population. UGT1A1*6 has predictive value for irinotecan toxicity in the Japanese patient population; 25 however, owing to its low frequency in European-Americans and African-Americans, genotyping this variant is unwarranted in non-Asian populations. Not only do population differences in the frequency of DME alleles affect sensitivity and specificity parameters of a genotype as a clinical assay, but also the interpretation of the growing body of genotype/phenotype association studies. Our findings confirm for UGT1A, what has already been described more globally, 61, 74 namely that LD patterns vary substantially among populations. As a SNP in one population may define a different haplotype than the same SNP in a different population, the strength of the genotype/phenotype association of interest will need to be confirmed in independent populations. This further compounds the already recognized challenge of identifying the true association between any given UGT1A genotype and a specific phenotype related to a specific substrate. Comparative genomics analysis and selection of segments for re-sequencing Primers were designed to amplify the coding sequences of UGT1A1, UGT1A6, UGT1A9 and the shared exon 5 in mouse. These segments were amplified by PCR and used as probes to screen a mouse BAC library (Mus musculus, RPCI-23). To screen the BAC libraries of additional species, probes for the two most distant known UGT1A genes were used. The probes used are as follows: 1A7 and the shared exon 5 in rat (Rattus norvegicus, RPCI-32), 1A1 and 1A9 in dog (Canis familiaris, RPCI-81), and 1A8 and the shared exon 5 in the olive baboon (Papio anubis, RPCI-41). The extent of coverage of the UGT1A cluster was further assessed in each positive clone by PCR, with successful amplification of a locus indicating inclusion of that gene in a clone. Selected clones representing the full extent of the UGT1A cluster in each species were then sequenced by the random shotgun approach. 76 Repetitive elements in all BAC clone sequences were masked using RepeatMasker (www.repeatmasker.org) and aligned to the human UGT1A reference sequence (AF297093) using MultiPipMaker (http://bio.cse.psu.edu/ pipmaker) 77 to identify conserved sequences across species. The single coverage option of this program was used to identify the best matches to the human sequence. Noncontiguous sequences in the non-human species were allowed to match contiguous sequences in the human sequence, as the UGT1A first exons are not in the same order and number across species 2 (our data). All UGT1A exons (excluding the pseudogenes) and adjoining noncoding regions demonstrating high percentage sequence identity across the five species were selected for sequencing in the human sample set.
Materials and methods
Population samples
PCR amplification and sequencing
Primers for amplifications and sequencing of human samples were designed based on GenBank sequence entry AF297093; all nucleotide positions in this article refer to this sequence. Primer sequences and PCR conditions are available through PharmGKB (http://www.pharmgkb.org); note that free registration is required to access this information. PCR products were prepared for sequence analysis by treatment with exonuclease I and shrimp alkaline phosphatase (United States Biochemicals, Cleveland, OH, USA). Dyeterminator sequencing on both strands was performed according to the manufacturer's protocol (BigDye version 3.1, Applied BioSystems, Foster City, CA, USA) and products were analyzed on ABI 3100, 3700, or 3730 automated sequencers. Data were imported into Polyphred 4.0.5.
78
SNPs and every genotype call were manually confirmed by visual inspection of high-quality chromatograms in Consed.
Statistical analysis
For interspecies comparisons, multiple sequence alignments were generated using MLAGAN (http://lagan.stanford.edu/ lagan_web/index.shtml). 79 Quantitative descriptors of human population variation -S, the total number of polymorphic sites in the entire sample; p, the average number of site differences between any two sequences in the sample; and Tajima's D, a statistic that summarizes the distribution of allele frequencies in the sample -were calculated using SLIDER (http://genapps.uchicago.edu/slider/index.html). Pairwise LD |D 0 | was calculated from diploid data, 80 and the patterns of LD were visualized using LDPlotter (http://www.innateimmunity.net). The probability of an effect on function for each nsSNP was estimated using the computer algorithm SIFT. 46 
